BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Eli Lilly to Invest $5 Billion in New Virginia API and Bioconjugate Manufacturing Facility

New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other ad...

September 17, 2025 | News

China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...

September 17, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...

September 16, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Samsung Biologics Expands Presence in Japan with New Tokyo Office

Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and ...

September 09, 2025 | News

Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma

Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...

September 08, 2025 | News

China’s Biocytogen and Germany’s Merck KGaA Join Forces on Antibody-LNP Delivery Innovation

-Biocytogen Pharmaceuticals , a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative te...

September 05, 2025 | News

Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability

Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...

September 01, 2025 | Company results

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

Asia Bio Innovation Summit 2025 Highlights ADC and CGT as Dual Engines of Biopharma Innovation

Asia Bio Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT. Asia B...

August 25, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Stay Connected